<P> Whether angiotensin receptor blockers may or may not increase the risk of myocardial infarction (heart attack) was announced in BMJ and was debated in 2006 in the medical journal of the American Heart Association . To date, there is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI . </P> <P> In the VALUE trial, the angiotensin II receptor blocker valsartan produced a statistically significant 19% (p = 0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with amlodipine . </P> <P> The CHARM - alternative trial showed a significant + 52% (p = 0.025) increase in myocardial infarction with candesartan (versus placebo) despite a reduction in blood pressure . </P> <P> Indeed, as a consequence of AT1 blockade, ARBs increase Angiotensin II levels several-fold above baseline by uncoupling a negative - feedback loop . Increased levels of circulating Angiotensin II result in unopposed stimulation of the AT2 receptors, which are, in addition upregulated . Unfortunately, recent data suggest that AT2 receptor stimulation may be less beneficial than previously proposed and may even be harmful under certain circumstances through mediation of growth promotion, fibrosis, and hypertrophy, as well as proatherogenic and proinflammatory effects . </P>

Which drug is indicated for the treatment of hyperkalemia